Autolus Therapeutics annual free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Autolus Therapeutics Free Cash Flow (FCF) History (AUTL)
Autolus Therapeutics reported −$302.6M in free cash flow for fiscal 2025, a decrease of $74.3M from the previous fiscal year, with a free cash flow margin of −401.40%.
View full Autolus Therapeutics company overviewAutolus Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$302.6M | −$74.3M | — | −401.40% |
| 2024 | 2024-12-31 | −$228.3M | −$71.8M | — | −2256.38% |
| 2023 | 2023-12-31 | −$156.6M | −$33.4M | — | −9221.02% |
| 2022 | 2022-12-31 | −$123.1M | $3.6M | — | — |
| 2021 | 2021-12-31 | −$126.7M | $5.7M | — | — |
| 2020 | 2020-12-31 | −$132.4M | −$12.6M | — | — |
| 2019 | 2019-12-31 | −$119.8M | −$79.2M | — | −4120.53% |
| 2018 | 2018-09-30 | −$40.7M | −$21.4M | — | −2889.55% |
| 2017 | 2017-09-30 | −$19.2M | −$7.5M | — | −1136.21% |
| 2016 | 2016-09-30 | −$11.7M | — | — | −965.68% |
Autolus Therapeutics quarterly free cash flow
Q4.18
Q2.19
Q3.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$26.0M | $54.1M | — | −56.87% |
| Q1 2026 | 2026-03-31 | −$68.0M | $15.8M | — | −259.38% |
| Q4 2025 | 2025-12-31 | −$68.2M | −$19.2M | — | −280.82% |
| Q3 2025 | 2025-09-30 | −$72.3M | $14.0M | — | −341.17% |
| Q2 2025 | 2025-06-30 | −$80.1M | −$28.1M | — | −382.63% |
| Q1 2025 | 2025-03-31 | −$83.8M | −$42.8M | — | −933.07% |
| Q4 2024 | 2024-12-31 | −$49.0M | −$22.7M | — | −169124.14% |
| Q3 2024 | 2024-09-30 | −$86.3M | −$44.6M | — | — |
| Q2 2024 | 2024-06-30 | −$51.9M | −$9.4M | — | — |
| Q1 2024 | 2024-03-31 | −$41.0M | $5.0M | — | −406.77% |
| Q4 2023 | 2023-12-31 | −$26.3M | $12.9M | — | — |
| Q3 2023 | 2023-09-30 | −$41.7M | −$8.5M | — | — |
| Q2 2023 | 2023-06-30 | −$42.5M | $575,000 | — | — |
| Q1 2023 | 2023-03-31 | −$46.0M | −$16.6M | — | — |
| Q1 2021 | 2021-03-31 | −$39.2M | −$12.6M | — | −14588.48% |
| Q4 2020 | 2020-12-31 | −$33.2M | $1.7M | — | — |
| Q3 2020 | 2020-09-30 | −$43.1M | −$14.8M | — | — |
| Q2 2020 | 2020-06-30 | −$29.5M | −$6.6M | — | −10053.24% |
| Q1 2020 | 2020-03-31 | −$26.7M | $7.2M | — | −7890.53% |
| Q4 2019 | 2019-12-31 | −$34.9M | −$20.3M | — | −11279.61% |
| Q3 2019 · Sep 30 | 2019-09-30 | −$28.3M | — | — | −9517.85% |
| Q3 2019 · Jun 30 | 2019-06-30 | −$22.9M | — | — | −6762.13% |
| Q2 2019 | 2019-03-31 | −$33.8M | — | — | −1723.37% |
| Q4 2018 | 2018-09-30 | −$14.5M | — | — | −4730.62% |
Autolus Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$132.4M to −$302.6M, a net decrease of $170.2M. Autolus Therapeutics's latest reported quarter, Q2 2026, generated −$26.0M in free cash flow, an increase of $54.1M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Autolus Therapeutics filings at SEC.gov ↗